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Both hospital and outpatient products, as well as orphan drugs have been included in 
this analysis. All medicinal products have been assessed on the INN level, without 
differentiating original, innovative products from generics. In addition to general sta-
tistical analysis, the GDP adjusted comparison has also been performed. Subsequently 
we have also conducted more detailed analysis of the following ATC groups, known 
to be major health care cost drivers: C (cardiovascular), J (anti-infective), L (oncology), 
M (musculo-skeletal) and N (neurology, psychiatry). RESULTS: As expected, linear 
correlation between national GDP and number of reimbursed INNs have been 
observed. However, major differences in mentioned ATC groups have revealed the 
inconsistency of the current HTA activities across countries leading to sometimes 
unfair treatment possibilities for patients with different diseases which could have not 
been justiﬁed by unequal socio-economic characteristics of investigated countries. 
CONCLUSIONS: There is a strong need for the continuous education of national 
decision makers on the principles and processes of the HTA. New innovative ideas of 
ﬁnancing the health care in developing countries are urgently needed in order to ensure 
ethical standards in health care and subsequent patient access to cost effective treat-
ment, but at the same time to engage patients in investing in their personal health and 
wellbeing.
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OBJECTIVES: Since the 1990s, many articles have documented problems with US 
payers’ utilization of pharmacoeconomic studies for decision-making. By replicating 
an in-depth survey methodology, this study aimed to determine the extent to which 
US practices had changed over the past decade. METHODS: Semi-structured explor-
atory interviews were conducted in 2007 to develop a survey instrument—ﬁelded 
in 2007–08 with key formulary decision-makers at US insurers and US public payers 
in 9 pre-identiﬁed categories. The structured set of questions examined US health 
care payers’ 1) use of, and attitudes and perceptions regarding, pharmacoeconomic 
information, and 2) opinions about how pharmaceutical manufacturers present 
pharmacoeconomic information. RESULTS: Compared to 10 years ago, U.S. payers 
regard pharmacoeconomic information much more favorably, despite variation in their 
use of and attitudes toward pharmacoeconomics. Payers cluster in three groups: a 
minority who use pharmacoeconomic information frequently and rigorously; a broader 
group who examine pharmacoeconomic information informally and do rigorous analy-
sis occasionally; and a group who only review pharmacoeconomic information in 
broad terms along with other drug-related information. Across all categories, payers 
acknowledge that the quality of pharmacoeconomic studies has improved. Payers 
suggest that pharmacoeconomic studies often “answer the wrong questions”—e.g., by 
failing to identify the subset(s) of patients where the drug is most effective. Payers 
remain skeptical towards pharmacoeconomic information and studies provided/spon-
sored by industry—e.g., when they perceive companies present only favorable studies. 
Increasingly, payers separate clinical reviews from pharmacoeconomic evaluations; the 
latter may be integrated with rebating discussions. CONCLUSIONS: US payer atti-
tudes about and use of pharmacoeconomic information have improved; however, 
formal, rigorous use of cost-effectiveness analysis is not the norm. Most payers 
foresee their organizations using pharmacoeconomic evaluation slightly more and 
would welcome a neutral entity that produced pharmacoeconomic evidence—although 
some question whether even government funding could insulate it from industry and 
political inﬂuence.
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OBJECTIVES: Social Health Insurance (SHI) and National Health Service (NHS) are 
two main choices for health reform. China’s health reform during last decade is basi-
cally SHI-oriented, especially after the implementation of “Basic health Insurance 
of Urban Workers” since 1998. Theoretically speaking, a NHS system will invest 
more on preventive care than an SHI system. This research investigates the effect of 
increasing health insurance coverage on health expenditure in China, especially 
through the speciﬁc channel of preventive care. METHODS: We estimates the health 
care expenditure function with province-level panel data from 1991–2007 of China. 
The key determinates we examined are social health insurance policy implication (the 
increaseing coverage of health insurance) and the share of preventive care in health 
disbursement. Other determinants are those usually in literatures including GDP, 
doctor and beds supply, population, aging. The independent variables of interests 
are per capita health expenditure, hospitalization expenses, inspecting commission 
and medical expenses. A generalized difference-in-difference method is used to assess 
the effect of adoption of social health insurance. IV methods are used to control 
the possible endogeneity problems. RESULTS: The increasing coverage of health 
insurance is expected to contribute to health care expenditure increasing. The more 
is the spending of preventive health care, the lower the health expenditure is. More-
over, we ﬁnd social health insurance coverage has a crowding-out effect on preventive 
care expenditure. Other variables’ effects are similar to the results from literatures. 
CONCLUSIONS: “Low accessibility and high costs in health care service” is key 
problem of China’s health care system right now. The SHI oriented health reform 
is a driver of health care expenditure increasing. China has just stated of a new 
comprehensive heath care system reform. The move to SHI may be politically correct, 
but is not the best option for China. It will lead to long-term and deep crisis in the 
health sector.
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OBJECTIVES: To estimate the hospitalisation cost of ICU patients admitted to the 
TUHL in the region of Thessaly, in Greece.        METHODS: The ICU chosen is the only 
tertiary university ICU in the whole region of Thessaly accounting 27% of the total 
ICU beds. The study sample consisted of all patients (elective and emergency admis-
sions) admitted to the respective TUHL in 2006. Clinical data were derived from    
patients’ medical records on a retrospective basis whereas economic data were derived 
from the Hospital’s Financial Department. The analysis included direct costs, using 
an up-down approach under NHS perspective. The nominal and actual hospitalization 
cost per ICU patient were based on the resource utilisation and the annual hospital 
balance sheets on NHS prices in Euros. RESULTS: 312 have been admitted to the 
ICU with a total direct cost of a4,799 million suffering from stroke, COPD, cancer,  
heart, trauma, pneumonia with a mean length of stay 8.87 days. The mean cost per 
hospitalisation day in the ICU was estimated at a1,734. Mean actual cost per patient 
is estimated at a15,382 whereas social insurance funds reimburse only a1,666. Person-
nel costs are the major cost component accounting for 31% of the total cost, while 
the pharmaceuticals account for 23%, laboratory 11%, supply and oxygen 17%, 
infrastructure-hotel services expenses 18%. CONCLUSIONS: This research results in 
some meaningful conclusions for effecting changes in hospital policies for better utili-
zation of ICU resources, for optimizing patient care and incorporating economic  
assessment in decision-making.
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OBJECTIVES: The objective of the study is to obtain behaviour of the cost’s relative 
average weights of the assistance with the retrospective application of the Adjusted 
Clinical Groups (ACG’s) in 16 teams of Primary Care with an attended population 
in the clinical practice use.   METHODS: Multicentre, retrospective study based on 
electronic records of patients seeking care during 2008 in the regions of Aragon, 
Balears and Catalonia. Main measurements: universal variables (age, sex, health 
service-family practice/paediatrics) and dependent variables: episodes and total       
cost (visits, diagnostic test, referrals, drugs). The ACG case-mix System software 
(version 7.1; N  106) classiﬁed subjects into a single category for a given annual           
resource consumption. The model of cost per each patient was established differencing         
the ﬁx cost and the variable. Outlier patients were considered those surpassing 
T  Q31.5(Q3-Q1)  a1,778.6 for total cost expenditure. Log transformation of 
the dependent variable was carried out to reduce skewness of the distribution and           
make it close to normal. Explanatory power was calculated by coefﬁcients of deter-
mination (R2). Statistical software: SPSS, p  0.05. RESULTS: The total number of 
the studied patients was 227,235 (intensity of use: 75.6%), with an average 4.5         o 3.2 
episodes. The age average was of 44.1 o 23.7 years, 56.6% women (13.5% paediat-
rics). The distribution of costs was a148,657,137. The total unitary cost per patient/
year 654.2 o 851.7a (relative weights of reference). Patient’s case-mix: 57.2% of 
the study population was grouped into 10 ACG. The explanatory power of the 
ACG classiﬁcation system was 36.3% (Ln: 41.2%), p  0,001. 6.2% of patients    
were considered Outliers (N  14.066). It details the form skewness and the average         
relative weights per each category of ACG’s classiﬁcation. CONCLUSIONS: The 
ACG are an acceptable system of classiﬁcation of patients in situation of clinical 
practice use. Some ACG classiﬁcation categories should be separeted due to the high        
outliers number.
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OBJECTIVES: To study how concentrated the Finnish pharmaceutical market is in 
certain medicine groups. During the last decade the Finnish authorities have imple-
mented different acts to increase the competition in the pharmaceutical market.     
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METHODS: We examined the concentration of the pharmaceutical market by using 
the Herﬁndahl-Hirschmann Index. We calculated the index for 12 different medicine 
groups in 2002–2008. Ten of these groups were prescription medicines and two were     
self-care medicines. The index is calculated by summing up the squares of the market 
shares for all the ﬁrms operating in the medicine group. It is important that all medi-
cines in each group can be substituted to each other. The index value varies between 
1/n  1, n  ﬁrms. Greater value of the HHI indicates greater concentration. If HHI 
is below 0.18 there is no concentration at all. RESULTS: In 2002 the total HHI 
average for the 12 groups was 0.30 as in 2008 it was 0.22. In anti-dementia drugs    
the index dropped from 0.48 to 0.23. In triptans the index dropped from 0.40 to 0.17. 
The smallest index was seen in antiallergics. In 2002 the index in this group was 0.14 
and in 2008 it was 0.12. In 2008 the most concentrated group according to the index 
was the protone pump inhibitors. The index in this group was 0.38. CONCLUSIONS: 
From 2002 to 2008 the concentration in medicine groups has clearly diminished. The 
difference between these groups is partly due to patents. The two self-care medicine   
groups used in the study are clearly less concentrated than the prescription medicine 
groups. However, the average for all 12 groups is 0.22 and exceeds the index point 
of 0.18. This indicates that among the medicine groups used in calculations the market 
is still concentrated.
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OBJECTIVES: To examine if the introduction of a lump sum reimbursement system 
for pharmaceuticals in Belgian hospitals for hospitalized patients resulted in shifts 
in Health Insurance expenses (third party payer) for pharmaceuticals from an in-
patient setting (hospitalized patients) to an out-patient setting (day clinic, public 
pharmacies, . . .), based on an analysis of ﬁnancial data of NIHDI. METHODS: In july 
2006, a partial (approximately 75% of the expenses) lump sum reimbursement 
system was introduced for standard medication (excluding new expensive drugs, 
oncolytics, orphan drugs, . . .) ﬁxing budgets per hospital, per hospitalization, based 
on patient proﬁles (APRDRG, All patients Reﬁned Diagnosis Related Groups) and 
ﬁnancial data. Using registered ﬁnancial data from NIHDI the evolution of the Health 
Insurance expenses for pharmaceuticals in hospitals was examined. RESULTS: 
The yearly expenses for pharmaceuticals for hospitalized patients grew with 8.0%, 
0.2%, 2.0%, 0.1% and 1.6% in the period 2003–2008. For patients in day 
clinic the growth was respectively 23.7%, 11.7%, 5.8%, 19.3% and 17,9%. 
For patients in public pharmacies these ﬁgures were 8.2%, 1.2%, 2.3%, 6.2% 
and 12.2%. CONCLUSIONS: Evaluation of the data shows no changes in the trend 
in evolution of the expenses for any type of patients other than leveling of the growth 
in the period 2005–2006—similar to the evolution of expenses for pharmaceuticals 
in the other OECD countries—and a additional growth in expenses in public pharmacies 
(6,2%) due to the inclusion of self-employed persons in the general system for com-
pulsory health insurance in 2008. Analysis shows no shifts in expenses from one 
setting to another.
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OBJECTIVES: In view of the 6-fold increase in drug expenditure over the past decade 
in Ireland, we set out to identify primary areas of utilisation and expenditure under 
the Community Drugs Schemes and explore strategies for cost containment. 
METHODS: We examined the Statistical Analysis of Claims and Payments for 
2007/2008 from the Primary Care Reimbursement Service (PCRS). This is a deﬁnitive 
measure of general practitioner prescribing rates and enabled us to determine utiliza-
tion and expenditure. We applied the autoregressive integrated moving average 
(ARIMA) model to the national prescribing database to predict future expenditure on 
medicines. RESULTS: In 2008 expenditure under the Community Drugs Schemes was 
a2.289 billion with over 60.5 million prescription items. The ARIMA model predicts 
that expenditure will continue to rise reaching a2.3–a3 billion by 2012. The 60.5 
million prescription items are distributed as follows: General Medical Services Scheme 
(GMS) 73%, Long Term Illnesses Scheme 4% (both free to patients), Drug Payments 
Scheme 22%, High Technology Drugs and others account for the remaining 1%. The 
major therapeutic classiﬁcations by cost under the GMS are Cardiovascular System 
23.9%, Nervous System 20.5%, Alimentary Tract and Metabolism 15.4%. Cost 
containment measures could include: increasing generic drug utilisation rates from 
18.3% (2.4% unbranded, 15.9% branded; EU average ^50%); decreasing wholesale 
margin from 15%; changing current drug schemes by introducing disinvestment 
measures and patient co-payments; reducing the pharmacy 50% mark-up and intro-
ducing reference pricing whilst continuing to reward innovation. CONCLUSIONS: 
It is clear that the current trend of increasing drug expenditure will continue and 
the measures we have suggested above would be efﬁcient strategies for cost 
containment.
PHP43
INTERNATIONAL PAYER RESARCH: COMPARING AND CONTRASTING 
PAYER ROLES AND RESEARCH METHODS IN CANADA, SPAIN, AND 
THE UK
de Cambra S1, Mladsi D2, Neale S3
1RTI Health Solutions, Barcelona, Spain, 2RTI Health Solutions, Research Triangle Park, NC, 
USA, 3RTI-Health Solutions, Ottawa, Ontario, Canada
OBJECTIVES: Global pharmaceutical companies often conduct coordinated, multi-
country studies to elicit information from payers and those who inﬂuence their deci-
sions. Such studies can inﬂuence global product value strategy and increase the 
likelihood of positive pricing and reimbursement (P&R) decisions. Differences in P&R 
systems across markets must be considered. The aim of this study was to compare 
payer roles in three pharmaceutical markets (UK, Spain, Canada), and to evaluate 
the usefulness of various qualitative research methods in eliciting information to 
inform a global product value strategy. METHODS: We conducted a review of pub-
licly available guidance and qualitative payer research to develop a framework for 
comparing optimal approaches to qualitative payer research. We compared the 
levels at which pricing, reimbursement, and market access decisions are made (e.g., 
national, regional, local, hospital), bodies inﬂuencing payer decisions (e.g., health 
technology assessment agencies), and the processes of engagement among physicians, 
patients, and payers. Implications of various qualitative and quantitative research 
techniques on a pharmaceutical company’s ability to devise an effective global strategy 
are discussed. RESULTS: Treatment location (outpatient drug, hospital only) and type 
of prescriber must be considered when determining the research strategy in Spain. 
In Canada, provincial drug plans make reimbursement decisions for outpatient 
drugs considering Common Drug Review recommendations. Hospital formulary com-
mittees assess drugs for hospital use. NICE, the Scottish Medicines Consortium and 
the All Wales Medicines Strategy Groups make decisions at the national level in the 
UK while Primary Care Trusts make funding decisions in the absence of NICE 
appraisal in England. CONCLUSIONS: For multi-country payer research to be useful 
for devising a global value strategy it is important to understand the pricing and 
reimbursement systems in different countries and to identify properly the key 
stakeholders.
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OBJECTIVES: Assessment of health technology (HTA), including pharmaceuticals, 
devices, procedures and organizational systems plays an increasingly important 
role in health care systems by providing structured, evidence-based input to policy-
making. HTA is ﬁrmly established in Europe, North America and Australasia, and is 
growing rapidly in Asia and Latin America. We investigated the organisation and 
inﬂuence of HTA in middle-income countries on real decision-making over pharam-
ceutical budgets. METHODS: We selected middle-income countries where HTA 
activities are establihsed to some extent: Argentina, Brazil, China, Colombia, Israel, 
Mexico, Philippines, Korea, Taiwan, Thailand, and Turkey. We collected and reviewed 
relevant information to describe the health care and reimbursement systems and how 
HTA relates to coverage decision making of pharmaceuticals using a common tem-
plate. The country proﬁles were supplemented by information from a structured 
web-survey among professionals working in public and private health insurance, 
industry, regulatory authorities, ministries of health, academic units or HTA agencies. 
RESULTS: The use and implementation of HTA recommendations in reimbursement 
decision-making is still in its early stages. We found that in South Korea, Taiwan, 
Brasil and Mexico HTA was more developed, with guidelines for manufacturers 
submissions, a link to the pricing of new treatments and some requirement for data 
to be adapted for local costs epidemiology. CONCLUSIONS: The study provides 
evidence of the development of HTA in coverage decision making in middle-income 
countries. Increased health care spending and the resulting access to modern technol-
ogy give a strong impetus to HTA. The assessment and regulation of pharmaceuticals 
are advanced in relation to other technologies. HTA is developing with uneven speed 
in middle-income countries; many countries are building on the organisational and 
methodological experience from established HTA agencies in Europe, Australia and 
Canada.
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OBJECTIVES: Elicit the individual willingness to pay (WTP) for a QALY. METHODS: 
Web-based contingent analysis included 1091 respondents, representative of the Dutch 
population. Individuals solved 5 scenarios with two health states each. They initially 
valued health states on VAS scale, then indicated which health state was worse and 
ﬁnally expressed their WTP for avoiding a given decline in health. WTP was elicited 
in an open-ended format and from a payment scale. Respondents had to indicate the 
degree of certainty in the answers provided. WTP/QALY was calculated one for every 
utility elicitation technique, WTP elicitation technique (payment scale and open-ended 
questions) and each scenario. The heterogeneity in WTP/QALY ratios was examined 
from the perspective of 1) household income, and 2) the level of certainty in WTP 
